[go: up one dir, main page]

GR1010977B - Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof - Google Patents

Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof

Info

Publication number
GR1010977B
GR1010977B GR20240100390A GR20240100390A GR1010977B GR 1010977 B GR1010977 B GR 1010977B GR 20240100390 A GR20240100390 A GR 20240100390A GR 20240100390 A GR20240100390 A GR 20240100390A GR 1010977 B GR1010977 B GR 1010977B
Authority
GR
Greece
Prior art keywords
glucagon
analogue
peptide
preparation
parenteral formulation
Prior art date
Application number
GR20240100390A
Other languages
Greek (el)
Inventor
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αναστασια Λεωνιδα Καλασκανη
Βασιλικη Χρηστου Σαμαρα
Ευαγγελος Ανδρεα Καραβας
Μανωλης Στυλιανου Φουστερης
Αντωνης Καπετανακης
Αρετη Ψαρρου
Original Assignee
Φαρματεν Α.Β.Ε.Ε.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Φαρματεν Α.Β.Ε.Ε., filed Critical Φαρματεν Α.Β.Ε.Ε.,
Priority to GR20240100390A priority Critical patent/GR1010977B/en
Publication of GR1010977B publication Critical patent/GR1010977B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά φαρμακευτικά σκευάσματα για παρεντερική χορήγηση που περιέχουν λιραγλουτίδη ως δραστική ουσία. Η παρούσα εφεύρεση παρέχει επίσης τη μέθοδο παρασκευής του εν λόγω σκευάσματος, η οποία περιλαμβάνει συγκεκριμένες συνθήκες παρασκευής για τη διασφάλιση του προφίλ ποιότητας του τελικού προϊόντος.The present invention relates to pharmaceutical formulations for parenteral administration containing liraglutide as an active substance. The present invention also provides the method of preparing said formulation, which includes specific manufacturing conditions to ensure the quality profile of the final product.

GR20240100390A 2024-05-23 2024-05-23 Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof GR1010977B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20240100390A GR1010977B (en) 2024-05-23 2024-05-23 Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20240100390A GR1010977B (en) 2024-05-23 2024-05-23 Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof

Publications (1)

Publication Number Publication Date
GR1010977B true GR1010977B (en) 2025-06-13

Family

ID=96809549

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20240100390A GR1010977B (en) 2024-05-23 2024-05-23 Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof

Country Status (1)

Country Link
GR (1) GR1010977B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633390B1 (en) * 2003-06-03 2012-01-18 Novo Nordisk A/S Stabilized pharmaceutical glp-1 peptide compositions
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
WO2018096460A1 (en) * 2016-11-22 2018-05-31 Biocon Research Limited Pharmaceutical compositions of glp-1 analogues
CN114146163A (en) * 2021-12-07 2022-03-08 苏州天马医药集团天吉生物制药有限公司 Preparation method of semaglutide preparation
US20220088205A1 (en) * 2016-10-14 2022-03-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof
EP2394656B1 (en) * 2003-11-20 2023-12-13 Novo Nordisk A/S Pharmaceutical formulations comprising the peptide liraglutide and propylene glycol

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633390B1 (en) * 2003-06-03 2012-01-18 Novo Nordisk A/S Stabilized pharmaceutical glp-1 peptide compositions
EP2394656B1 (en) * 2003-11-20 2023-12-13 Novo Nordisk A/S Pharmaceutical formulations comprising the peptide liraglutide and propylene glycol
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
US20220088205A1 (en) * 2016-10-14 2022-03-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof
WO2018096460A1 (en) * 2016-11-22 2018-05-31 Biocon Research Limited Pharmaceutical compositions of glp-1 analogues
CN114146163A (en) * 2021-12-07 2022-03-08 苏州天马医药集团天吉生物制药有限公司 Preparation method of semaglutide preparation

Similar Documents

Publication Publication Date Title
CY1112892T1 (en) LASOXOXYPHINE TABLET AND ITS COVER
MX2019011491A (en) Niraparib formulations.
AU2018240540A1 (en) Novel compositions and methods
CY1115526T1 (en) PHARMACEUTICAL COMPOSITION WHICH INCLUDES PIMOBENDANI
BR112019000528A2 (en) ve-mediated distribution of small molecule-binding protein conjugates
ES3052569T3 (en) Oxadiazole compounds as transient receptor potential channel inhibitors
DE18837223T1 (en) STARCH-FREE SOFT CHEER FOR VETERINARY MEDICAL APPLICATIONS
CO2024011162A2 (en) NLRP3 inhibitors
MX2021003662A (en) Aminonordecane derivative, and preparation method therefor and application thereof.
GR1010977B (en) Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof
BR112023026909A2 (en) PHARMACEUTICALLY ACCEPTABLE SALT OF AP1189 ((E)-N-[1-(2-NITROPHENYL)-1-H-PYRROL-2-YL-ALLYLIDENOAMINO]-GUANIDINE), PHARMACEUTICAL COMPOSITION, SINGLE DOSAGE FORM, AND, ORAL FORMULATION
CL2023003146A1 (en) Methods for treating esophageal strictures
BR112022000760A2 (en) Compositions, method for preparing a long-acting conjugate of a physiologically active polypeptide and long-acting drug conjugate
CO2022001218A2 (en) Composition of micromolecular inhibitor of pi4kiiiα, method of preparation and use
US20020114832A1 (en) Pharmaceutical preparation comprising peppermint oil and caraway oil in delayed release form
PE20231943A1 (en) COMBINED ORAL FORMULATION THAT INCLUDES GEMIGLIPTIN AND DAPAGLIFLOZIN AND METHOD OF PREPARATION THEREOF
Yoon et al. Comparison of R (+)-α-lipoic acid exposure after R (+)-α-lipoic acid 200 mg and 300 mg and thioctic acid 600 mg in healthy Korean male subjects
EA201891646A1 (en) TABLETS KLOZAPINA WITH SLOWLY SHOWING AND METHOD OF THEIR PREPARATION
CA3097783C (en) Taste-masking formulation for ketone body compounds
ZA202404262B (en) Parenteral formulation of a glucagon-like peptide-1 analogue and method for preparation thereof
ZA202305155B (en) Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
WO2021245700A3 (en) Pharmaceutical lipid compositions of remdesivir
PL434081A1 (en) Preparation in the form of coated tablets containing a high dose of temozolomide and method of its production
MX2025009759A (en) A high bioavailability pharmaceutical composition of glp agonist for oral administration
MX2025008658A (en) Pharmaceutical compositions of green propellant

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20250707